Association between NAD (P) H: Quinone Oxidoreductase 1 C609T Gene Polymorphism and Risk Factors in Cases of Cervical Cancer in Indian Women
Kumari S., Agrawal S., Nigam N., Singh N., Singh S., Kumar P.
Laboratory Study with a reported sample of 142, published in J Midlife Health (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- J Midlife Health (2025)
- Reported sample size
- 142
- Source database
- Europe PMC
- PMID
- 41415141
- PMCID
- PMC12711174
- DOI
- 10.4103/jmh.jmh_47_25
Abstract (original English)
Introduction HPV infection is causative agent for cervical cancer, majority of HPV infections are low-grade, self-limited, and revert spontaneously in some HPV infection fails to clear this hints towards presence of certain genetic factors which predispose them to increase risk of pre-cancer and cancer. We aimed to investigate the factors which have bearing on rising cancer cases in India and to elucidate the genetic susceptibility distribution of NAD (P) H: quinone oxidoreductase 1 C609T gene polymorphism. Materials and methods Study recruited 142 women with biopsy-proven cervical cancer (the case group) and 142 women with normal cytology (the control group). DNA extracted from blood via QIAamp DNA mini kit. The DNA of each participant was amplified and the genotype and allelic frequency were compared. Results In our study, maximum women in the case group had stage II (69.7%) squamous cell carcinoma (97.2%). 75.4% of the cases had moderately differentiated carcinoma and had no treatment before (43.7%). Among cases, the prevalence of genotype CC, CT and TT was 42.3%, 19.7% and 38.0%, respectively compared to 54.9%, 13.4% and 31.7%, in controls. The odds of having CC (odds ratio [OR] =0.64; 95% confidence interval [CI] =0.38-1.08), CC or CT in contrast to TT (OR = 0.756; 95% CI = 0.46-1.23), CC in contrast to TT/CT (OR = 0.694; 95% CI = 0.44-1.10) was lesser in cases compared to
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.